[go: up one dir, main page]

PE20120305A1 - Compuestos heterociclicos derivados de benzotiazol y tetrahidroquinolina como inhbidores de bcl-2 y bcl-xl - Google Patents

Compuestos heterociclicos derivados de benzotiazol y tetrahidroquinolina como inhbidores de bcl-2 y bcl-xl

Info

Publication number
PE20120305A1
PE20120305A1 PE2011001249A PE2011001249A PE20120305A1 PE 20120305 A1 PE20120305 A1 PE 20120305A1 PE 2011001249 A PE2011001249 A PE 2011001249A PE 2011001249 A PE2011001249 A PE 2011001249A PE 20120305 A1 PE20120305 A1 PE 20120305A1
Authority
PE
Peru
Prior art keywords
bcl
halogen
alkyl
inhbiders
tetrahydroquinoline
Prior art date
Application number
PE2011001249A
Other languages
English (en)
Inventor
Jonathon Bayldon Baell
Chihn Thien Bui
Peter Colman
Dannete A Dudley
Wayne J Fairbrother
John A Flygare
Guillaume Laurent Lassene
George Nikolakopoulos
Carl Steven Rye
Brad Edmund Sleebs
Brian John Smith
Keith Geoffrey Watson
Steven W Elmore
Andrew M Petros
Andrew J Souers
Chudi Ndubaku
Original Assignee
Abbott Lab
Genentech Inc
Inst Medical W & E Hall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42316717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120305(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab, Genentech Inc, Inst Medical W & E Hall filed Critical Abbott Lab
Publication of PE20120305A1 publication Critical patent/PE20120305A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

REFERIDA A UN COMPUESTO HETEROCICLICO DE FORMULA (I), DONDE R1 ES ALQUILO C1-C6, ALQUENILO C2-C6, HALOGENO, ENTRE OTROS; n ES UN ENTERO DE 0 A 2; X1 ES CH2, O, S, SO, ENTRE OTROS; X2a, X2b Y X2c SON CH, CR2 O N; R2 ES CN, HALOGENO, NO2, ENTRE OTROS; A ES UN GRUPO (1), (2), (3), ENTRE OTROS; R3 ES CN, NO2, HALOGENO, ENTRE OTROS; B ES UN GRUPO (a) O (b); X3 ES NH, N(ALQUILO C1-C3), S; R4a ES ALQUILO C1-C4, ALQUINILO C2-C4, HALOGENO, ENTRE OTROS; R4b ES HALOGENO, NO2, CN, ENTRE OTROS; L ES ALQUILENO C1-C6, ALQUENILENO C2-C6, NH, S, ENTRE OTROS; E ES H, HALOGENO, FENILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO 6-(4-(BENZO[d]TIAZOL-2-ILCARBAMOIL)-1-METIL-1,2,3,4-TETRAHIDROQUINOXALIN-6-IL)PICOLINICO, ACIDO 6-(1-(BENZO[d]TIAZOL-2-ILCARBAMOIL)-1,2,3,4-TETRAHIDROQUINOLIN-7-IL)-3-(2-FENOXIETOXI)PICOLINICO, ACIDO 6-(1-(BENZO[d]TIAZOL-2-ILCARBAMOIL)-1,2,3,4-TETRAHIDROQUINOLIN-7-IL)-3-(2-(3-(DIMETILAMINO)FENOXI)ETOXI)PICOLINICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS INHIBEN LA ACTIVIDAD DE LAS PROTEINAS Bcl-2 Y Bcl-Xl Y SON UTILES EN EL TRATAMIENTO DEL CANCER, TROMBOCITEMIA, ENTRE OTRAS
PE2011001249A 2008-12-19 2009-12-17 Compuestos heterociclicos derivados de benzotiazol y tetrahidroquinolina como inhbidores de bcl-2 y bcl-xl PE20120305A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13947908P 2008-12-19 2008-12-19

Publications (1)

Publication Number Publication Date
PE20120305A1 true PE20120305A1 (es) 2012-04-09

Family

ID=42316717

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001249A PE20120305A1 (es) 2008-12-19 2009-12-17 Compuestos heterociclicos derivados de benzotiazol y tetrahidroquinolina como inhbidores de bcl-2 y bcl-xl

Country Status (21)

Country Link
US (3) US8114893B2 (es)
EP (1) EP2376085B1 (es)
JP (1) JP5683484B2 (es)
KR (1) KR101633532B1 (es)
CN (1) CN102325531B (es)
AU (1) AU2009335818A1 (es)
BR (1) BRPI0918337A2 (es)
CA (1) CA2747161C (es)
CO (1) CO6390110A2 (es)
CR (1) CR20110389A (es)
DO (1) DOP2011000198A (es)
EC (1) ECSP11011214A (es)
ES (1) ES2462715T3 (es)
IL (1) IL213547A0 (es)
MX (1) MX2011006514A (es)
NZ (1) NZ593536A (es)
PE (1) PE20120305A1 (es)
RU (1) RU2561109C2 (es)
SG (1) SG172266A1 (es)
WO (1) WO2010080478A1 (es)
ZA (1) ZA201104463B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009011210A (es) 2007-04-16 2009-10-30 Abbott Lab Inhibidores de mcl1 de indol 7-no sustituido.
WO2009085216A2 (en) 2007-12-20 2009-07-09 Squicor Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
ES2462715T3 (es) * 2008-12-19 2014-05-26 Genentech, Inc. Compuestos y métodos de uso
MX2011006509A (es) * 2008-12-19 2011-10-19 Genentech Inc Compuestos heterociclicos y métodos de uso.
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
EP2675275B1 (en) 2011-02-14 2017-12-20 The Regents Of The University Of Michigan Compositions and methods for the treatment of obesity and related disorders
WO2012177927A1 (en) 2011-06-21 2012-12-27 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
US8889675B2 (en) 2011-10-14 2014-11-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI561521B (en) * 2011-10-14 2016-12-11 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI571466B (zh) * 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑
US8940737B2 (en) 2011-10-14 2015-01-27 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
MX2014007093A (es) 2011-12-13 2014-10-13 Buck Inst For Res On Aging Metodos para mejorar terapias medicas.
US20150064137A1 (en) 2012-04-17 2015-03-05 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US9365581B2 (en) 2013-05-02 2016-06-14 The Regents Of The University Of Michigan Deuterated amlexanox
RU2550346C2 (ru) * 2013-09-26 2015-05-10 Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
EP3060563B1 (en) 2013-10-25 2018-05-02 Novartis AG Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
EP3097078B1 (en) * 2014-01-24 2022-05-25 Purdue Pharma LP Pyridines and pyrimidines and use thereof
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
EP3669881B1 (en) 2014-01-28 2022-03-30 Buck Institute for Research on Aging Compositions for use in the treatment of senescence-assiocated eye disease and disorders
CN103804367B (zh) * 2014-02-28 2016-09-14 天津药物研究院 苯并氮杂卓衍生物、其制备方法和用途
EP3125884B1 (en) 2014-04-04 2019-11-06 The Regents of the University of Michigan Small molecule inhibitors of mcl-1 and uses thereof
US11331328B2 (en) 2014-05-05 2022-05-17 Bioventures, Llc Compositions and methods for inhibiting antiapoptotic Bcl-2 proteins as anti-aging agents
US9353060B2 (en) * 2014-07-08 2016-05-31 Dow Agrosciences Llc Process for the preparation of 3-hydroxypicolinic acids
CA2955972A1 (en) 2014-07-22 2016-01-28 Bioventures, Llc. Compositions and methods for selectively depleting senescent cells
EP3174890B1 (de) * 2014-07-28 2019-03-13 Merck Patent GmbH Metallkomplexe
WO2016054483A1 (en) 2014-10-03 2016-04-07 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
AU2015360621A1 (en) * 2014-12-09 2017-06-29 Abbvie Inc. Bcl-xL inhibitory compounds and antibody drug conjugates including the same
WO2016131100A1 (en) * 2015-02-18 2016-08-25 The Walter And Eliza Hall Institute Of Medical Research Methods of treating infectious diseases
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
WO2017132538A1 (en) 2016-01-29 2017-08-03 The Regents Of The University Of Michigan Amlexanox analogs
KR102494039B1 (ko) 2016-03-28 2023-01-30 프레시지 바이오싸이언시스, 인크. 암 치료를 위한 제약학적 조합물
US10807977B2 (en) 2016-04-21 2020-10-20 Bioventures, Llc Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
CN108251377B (zh) * 2018-01-16 2021-08-27 内蒙古大学 利用携带Xist Tale抑制性转录因子R6的R6-MEF制备饲养层细胞的方法
US12118414B2 (en) 2018-01-22 2024-10-15 Bioventures, Llc BCL-2 proteins degraders for cancer treatment
US12084423B2 (en) 2018-05-18 2024-09-10 Bioventures, Llc Piperlongumine analogues and uses thereof
EP3705109A1 (en) 2019-03-05 2020-09-09 Greenaltech, S.L. Carotenoids in the treatment of senescence-related diseases
EP4122928A4 (en) * 2020-04-20 2023-12-13 Shenzhen TargetRx, Inc. SOLID FORM OF PYRAZINE SUBSTITUTED NICOTINAMIDE AND PRODUCTION AND USE THEREOF
WO2021233948A1 (en) 2020-05-19 2021-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat a pathogen lung infection
EP4175644A1 (en) 2020-07-06 2023-05-10 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml)
JP2023553811A (ja) 2020-11-24 2023-12-26 ノバルティス アーゲー Ｂｃｌ－ｘｌ阻害剤抗体－薬物コンジュゲートおよびその使用方法
CN117794929A (zh) 2021-02-02 2024-03-29 法国施维雅药厂 选择性bcl-xl protac化合物及使用方法
WO2023172958A1 (en) * 2022-03-08 2023-09-14 Onkosxcel Therapeutics, Llc Stable formulations of talabostat
IL317101A (en) 2022-05-20 2025-01-01 Novartis Ag Antibody-drug conjugates of anticancer compounds and methods of using them
CN119562832A (zh) 2022-05-20 2025-03-04 诺华股份有限公司 Met bcl-xl抑制剂抗体-药物缀合物及其使用方法
KR20250027281A (ko) 2022-05-20 2025-02-25 노파르티스 아게 Epha2 bcl-xl 억제제 항체-약물 접합체 및 그의 사용 방법
WO2025087879A2 (en) 2023-10-23 2025-05-01 Institut National de la Santé et de la Recherche Médicale Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
WO2025111431A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd7 antibody-drug conjugates and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2332756A1 (fr) * 1975-11-26 1977-06-24 Squibb & Sons Inc Nouvelles 1, 4-benzoxazin-3(4h)-ones
DE19929785A1 (de) * 1999-06-29 2001-01-04 Bayer Ag Tetrahydrochinolinyl-6-methyldihydrothiadiazinon-Derivate und ihre Verwendung
SK12712002A3 (sk) * 2000-02-07 2003-02-04 Abbott Gmbh & Co. Kg Deriváty 2-benzotiazolylmočoviny a ich použitie ako inhibítorov proteínkináz
US7399759B2 (en) 2001-09-03 2008-07-15 Takeda Pharmaceutical Company Limited 1, 3-benzothiazinone derivatives and use thereof
JP4403305B2 (ja) * 2001-09-03 2010-01-27 武田薬品工業株式会社 １，３−ベンゾチアジノン誘導体および用途
PL210225B1 (pl) 2001-12-14 2011-12-30 Alcon Zastosowanie związku naśladującego dysmutazę ponadtlenkową jako środka do leczenia zaburzeń i chorób oczu
CA2620818A1 (en) 2005-09-02 2007-03-08 Astellas Pharma Inc. Amide derivatives as rock inhibitors
ES2657635T3 (es) * 2006-08-08 2018-03-06 Chugai Seiyaku Kabushiki Kaisha Derivado de pirimidina como inhibidor de PI3K y uso del mismo
MX2009011210A (es) 2007-04-16 2009-10-30 Abbott Lab Inhibidores de mcl1 de indol 7-no sustituido.
EP2134684B1 (en) 2007-04-16 2017-08-02 AbbVie Inc. 7-substituted indole as mcl-1 inhibitors
EP2193127A4 (en) * 2007-09-27 2011-09-14 Inst Medical W & E Hall BENZOTHIAZOLE COMPOUNDS
US20110172217A1 (en) 2008-09-05 2011-07-14 Shionogi & Co., Ltd. Ring-fused morpholine derivative having pi3k-inhibiting activity
MX2011006509A (es) * 2008-12-19 2011-10-19 Genentech Inc Compuestos heterociclicos y métodos de uso.
ES2462715T3 (es) 2008-12-19 2014-05-26 Genentech, Inc. Compuestos y métodos de uso

Also Published As

Publication number Publication date
SG172266A1 (en) 2011-07-28
HK1161094A1 (en) 2012-08-24
RU2011129789A (ru) 2013-01-27
MX2011006514A (es) 2011-10-11
CO6390110A2 (es) 2012-02-29
JP2012512887A (ja) 2012-06-07
BRPI0918337A2 (pt) 2017-05-30
US8518970B2 (en) 2013-08-27
CR20110389A (es) 2011-07-13
EP2376085A4 (en) 2012-08-15
ZA201104463B (en) 2012-09-26
CN102325531B (zh) 2014-04-02
US20140005190A1 (en) 2014-01-02
ECSP11011214A (es) 2011-09-30
ES2462715T3 (es) 2014-05-26
US20100190782A1 (en) 2010-07-29
NZ593536A (en) 2013-07-26
JP5683484B2 (ja) 2015-03-11
IL213547A0 (en) 2011-07-31
EP2376085A1 (en) 2011-10-19
KR20110114581A (ko) 2011-10-19
CN102325531A (zh) 2012-01-18
US20120184541A1 (en) 2012-07-19
CA2747161C (en) 2017-07-18
RU2561109C2 (ru) 2015-08-20
AU2009335818A1 (en) 2011-07-21
US9067928B2 (en) 2015-06-30
CA2747161A1 (en) 2010-07-15
WO2010080478A1 (en) 2010-07-15
US8114893B2 (en) 2012-02-14
EP2376085B1 (en) 2014-02-26
DOP2011000198A (es) 2012-08-31
KR101633532B1 (ko) 2016-06-24

Similar Documents

Publication Publication Date Title
PE20120305A1 (es) Compuestos heterociclicos derivados de benzotiazol y tetrahidroquinolina como inhbidores de bcl-2 y bcl-xl
PE20090773A1 (es) Derivados de morfolina pirimidina
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
PE20041016A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20090772A1 (es) Derivados de bencimidazol
PE20090649A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
PE20070189A1 (es) COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA
PE20091653A1 (es) Derivados sustituidos de pirazol y su uso
PE20061198A1 (es) Derivados de pirazol como inhibidores de cdk y gsk
PE20080906A1 (es) Derivados heteroarilo como inhibidores de citocina
PE20090895A1 (es) Derivados de triazol como inhibidores de la jak quinasa
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20120062A1 (es) Derivados de 1-bencil-2-amino-tetralina como inhibidores del transportador de glicina glyt1
PE20130385A1 (es) Derivados del acido naft-2-ilacetico para tratar el sida
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
PE20121506A1 (es) Compuestos triazolopiridinas como inhibidores de c-met
PE20110308A1 (es) 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
PE20141361A1 (es) Compuesto heterociclico dihidroxi aromatico
PE20090884A1 (es) Compuestos de indol como activadores de glucoquinasa
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
PE20091243A1 (es) Compuesto heterociclico fusionado

Legal Events

Date Code Title Description
FC Refusal